AKCEA THERAPEUTICS INC. overview

NEW YORK, NY / ACCESSWIRE / September 8, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Akcea Therapeutics, Inc. (NASDAQ:AKCA) Agreement Announcement: August 31, 2020 Transaction Details: Under the terms of the agreement, Ionis will commence a tender offer for all outstanding shares of Akcea common stock not already owned by Ionis at a...

NEW YORK, NY / ACCESSWIRE / September 3, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Akcea Therapeutics, Inc. (NASDAQ:AKCA) Agreement Announcement: August 31, 2020 Transaction Details: Under the terms of the agreement, Ionis will commence a tender offer for all outstanding shares of Akcea common stock not already owned by Ionis at a...

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy, and clinically relevant improvements in measures of quality of life compared to the natural history of the disease No new safety signals were identified TEGSEDI is an at-home subcutaneous injection BOSTON and...

BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 888-317-6003, passcode 7102411, or access the webcast at https://www.webcaster4.com/Webcast/Page/2327/34284 . A...

BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt, Ph.D. as Chief Executive Officer, effective immediately. Dr. McDevitt has served as interim CEO of Akcea since September 2019 and will continue to serve as a member of the Akcea board of directors. “With his experience at both Ionis and Akcea, Damien has the perspective and...

BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as senior vice president of new product strategy. In this role, Dr. Johnson-Pratt will drive Akcea’s corporate strategy and provide strategic support for the development and commercialization of new pipeline products. She will report to Damien McDevitt, Ph.D., interim chief executive...

BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare Disease Day 2020 and the effort to help more people learn about the impact of rare diseases on patients, their families and their caregivers. Throughout February, Akcea has highlighted important issues related to hereditary transthyretin (hATTR) amyloidosis, familial chylomicronemia syndrome (FCS) and other...

BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO, will present at the Cowen 40 th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 10:40 a.m. ET. The above listed date is subject to change. Details on presentation times or changes to...